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Background: Partial pancreatico-duodenectomy (PD) is the standard treatment for tumors of the pancreatic head.
Today, preservation of the pylorus has been widely accepted as the surgical standard in this procedure. A common
postoperative complication is the occurrence of delayed gastric emptying (DGE), which causes impairment of oral
intake andpatients’ quality of life, prolongation of hospital stay and delay of further treatment (for example adjuvant
chemotherapy). In a small number of two retrospective and one randomized studies, a modification by resection of
the pylorus with preservation of the stomach has shown to reduce DGE incidence. The aim of the present study is
to investigate the effect of pylorus resection on postoperative DGE in PD.
Methods/Design: Patients undergoing elective PD for any indication equal or older than 18 years and who have
given informed consent will be included. Patients will be randomized to either PD with pylorus preservation or PD
with pylorus resection and complete stomach preservation. Sample size (n = 89 patients per group) is calculated on
an assumed difference in DGE incidence of 20%. Primary study endpoint is DGE within 30 days; secondary
endpoints are operation time, blood loss, morbidity, mortality, hospital stay and quality of life (QoL).
Discussion: DGE is a relevant clinical problem following PD with a great impact on patients’ recovery, length of
hospital stay, QoL and consecutive adjuvant therapies. As there is no causal therapy, prevention of DGE is essential
to improve outcome. The technical modification of pylorus resection may offer a simple and effective method for
this purpose. The present study is designed to increase the existing body of evidence and potentially change the
future standard surgical procedure of PD.
Trial registration: German Clinical Trials Register DRKS00004191.
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Partial pancreatico-duodenectomy (PD) is the standard
treatment for tumors of the pancreatic head as well as
benign precursor lesions such as intraductal mucinous
neoplasia (IPMN) that require a resective surgical ap-
proach [1,2]. Classical partial pancreatico-duodenectomy
with resection of the distal stomach as the historical
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reproduction in any medium, provided the orTraverso, who introduced preservation of the pylorus
[3]. This modification (ppPD) has been widely accepted
to be equally effective compared to the classical
pancreatico-duodenectomy with regard to tumor recur-
rence and long-term survival in numerous studies [4]. A
well-known complication after either method of PD is
the occurrence of delayed gastric emptying (DGE) [5,6].
DGE causes impairment of oral intake and patients’
quality of life (QoL), prolongation of hospital stay and
delay of further relevant treatments (for example start of
adjuvant chemotherapy). This complication is regarded
as a functional impairment of the physiological propul-
sive regulation of the stomach and especially the pylorus.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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struction is superior to retrocolic duodeno-jejunostomy
in terms of the incidence of DGE [5,6]. In 2007, the
International Study Group of Pancreatic Surgery (ISGPS)
proposed a standardized definition of DGE with three
grades of severity (A-C) [7]. The grading system
included the use of a gastric tube, time to solid oral food
intake, symptoms like distension and vomiting as well as
the use of prokinetic medication. This definition was
evaluated in the patient collective in Heidelberg [8].
The overall frequency of DGE within this collective was
45%, including 28% DGE grade A, 8% grade B and 9%
grade C.
In a recent study published in 2010 by Kurahara et al.
[9], the frequency of DGE using the ISGPS definition
was examined in a retrospective data analysis compar-
ing 48 patients that underwent ppPD vs. 64 patients in
which the pylorus was resected (prPD). Resection was
limited to the pyloric ring with preservation of the en-
tire stomach. Reconstruction was then performed as a
gastro-jejunostomy in the distal antrum of the stomach.
In this study, DGE frequency was 34.8% after pylorus
preservation vs. 13.0% when the pylorus was resected.
This is in line with a retrospective study published in
2000 [10] comparing similar approached in 39 (ppPD)
vs. 33 (prPD) patients. DGE frequency was 33% vs. 12%
confirming an approximate difference of 20%. A current
Japanese publication by Kawai et al. [11] has focused on
the issue of pylorus resection in a randomized con-
trolled study. The authors have included 64 patients
with ppPD vs. 66 patients that underwent prPD with
the endpoint DGE between 7 days and 6 months post-
operatively. The observed frequency of DGE was 17.2%
and 4.5% respectively (P = 0.02). Although this study
showed a clear trend toward the results observed in the
former retrospective studies, several shortcomings (only
one randomized controlled trial (RCT), other studies
performed retrospectively, overall small number of
patients) do not allow drawing a final conclusion and
the surgical consequences. From the mentioned studies,
it seems reasonable that resection of the pylorus may
offer significant benefits in the postoperative phase
regarding the frequency of DGE and consecutive quality
of life and may be superior to the standard ppPD. Yet,
scientific evidence to support this hypothesis is rather
weak.
Therefore, the aim of the present study is to investi-
gate the two modifications of PD (ppPD vs. prPD) in a
randomized controlled setting to confirm or contradict
the hypothesis and show potential shortcomings of both
methods, which are not yet obvious. The results can
add more evidence to the current discussion and have a
potential impact on a widely performed standard oper-
ation in pancreatic surgery.Methods
Study population
The study population consists of all patients scheduled
for PD for any indication. Further inclusion criteria are
age equal or older than 18 years and having given
informed consent. Participation in another intervention
trial with interference of intervention and/or outcome of
this study and expected lack of compliance as well as
language problems represent the only exclusion criteria.
The study protocol has been approved by the local ethics
committee (University of Heidelberg S-121/2012).Randomization and surgical procedures
Patients are intraoperatively randomized to either of the
two groups after the surgeon has confirmed that preserva-
tion of the pylorus is technically and oncologically pos-
sible. Randomization is performed as an unstratified block
randomization with fixed block sizes in a 1:1 allocation
ratio using established randomization software. Block size
is kept confidential until completion of recruitment.
Standard PD with preservation of the pylorus is performed
by dividing the duodenum 2 cm distal of the pylorus
with a linear stapling device under preservation of the gas-
tric vessels along the lesser and the greater curvature.
Antecolic duodeno-jejunostomy is performed at the end
of the operation approximately 50 cm distal to the hepato-
jejunostomy by an end-to-side anastomosis using two-
layer monofilament atraumatic running sutures. Resection
of the pylorus is performed with preservation of the stom-
ach by the use of a linear stapling device with complete
preservation of the gastric vessels along both curvatures
to preserve perfusion of the distal stomach via the gastroe-
piploic arcade and the left gastric artery, respectively.
Antecolic gastro-enterostomy is performed by an end-to
-side gastro-jejunostomy using a two-layer running mono-
filament atraumatic suture technique as well. In both
groups, nasogastric tubes are removed as soon as mechan-
ical ventilation is stopped, usually at the end of the oper-
ation. Follow-up examinations are scheduled at day 7, 14
and 30 postoperatively. The study protocol is shown in
Figure 1.Study objectives
Primary efficacy endpoint is the frequency of post-
operative DGE according to the international ISGPS
definition (Table 1) 30 days after index operation, com-
pared between the two intervention groups [7]. Key
secondary endpoints are operation time (skin cut to last
knot), blood loss (ml), overall morbidity according to
the Clavien-Dindo classification [12], 30-day mortality,
postoperative hospital stay and QoL on postoperative
day 30.
Figure 1 Flow chart of the PROPP study.
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Selection bias
Consecutively screened and eligible patients will be
included after initiation of the study. In order to achieve
comparable intervention groups, patients will be allo-
cated concealed by intraoperative randomization at the
day of surgery using a centralized web-based tool (http://
randomizer.at). Block randomization will be performed
to achieve totally equal group sizes. A sufficient number
of patients will be recruited according to the sample size
calculation in order to prevent random error and toTable 1 DGE (grading A-C) according to the ISGPS definition
Grade Nasogastric tube Solid food intake
A 4-7d/reinsertion > d3 d7
B 8-14d/reinsertion > d7 d14
C >14d/reinsertion > d14 d21
DGE, delayed gastric emptying; ISGPS, International Study Group for Pancreatic Surgachieve sufficient power for hypothesis testing of the pri-
mary endpoint.Information bias
All surgeons who participate in this trial will be
instructed which treatment procedures are applicable in
both groups. Blinding of surgeons is not feasible due to
the nature of the interventions. However, patient and
observer documenting the endpoints during the post-
operative visits will be blinded.[7]
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Potential confounding will be controlled due to
randomization.
Performance bias will be minimized by applying a
standardized treatment manual for the surgical as well
as the perioperative procedures. Thus, all surgical proce-
dures will be defined in operation manuals. Moreover,
medical treatment including prokinetic drugs, proton
pump inhibition, antibiotics and octreotide analogs will
be defined a priori. Routine management of nasogastric
tubes and endoscopic examination in case of DGE will
be defined as well. Blinded assessment of the primary
endpoint 30 days after the surgical procedure will be
performed by independent observers (not aware of the
respective surgical procedure) to minimize measurement
bias. Patients will be kept blind to the randomized and
performed procedure. Unblinding of the patients will be
possible in situations requiring reinterventions.Sample size calculation
Sample size calculation is based on the primary endpoint
‘frequency of DGE 30 days after surgery’. On the basis of
previous literature mentioned in the background section,
an assumed absolute risk of 20% difference in DGE fre-
quency is the basis for the calculation assuming 32% DGE
in group 1 (ppPD) and 12% in group 2 (prPD).This leads
to a calculated number of 89 patients who have to be trea-
ted in each group assuring a power of 90% at a two-sided
level of significance of 5%. As the individual results for the
primary endpoint are available within 30 days after sur-
gery, the expected drop-out rate is small. Nevertheless, a
potential dilution of the treatment effect due to drop-outs
is taken into account; it is assumed that this can be
compensated by additional 10% of patients to be rando-
mized, and therefore the total sample size required
amounts to n = 198 patients.Documentation and data handling
All protocol-required information collected during the
trial is entered in the case report form (CRF). The com-
pleted CRFs are reviewed and signed by the investigator or
by a designated sub-investigator and sent to the Institute
for Medical Biometrics and Informatics (IMBI) for data
entry. The data will be managed and analyzed in the joint
unit of the clinical study center and IMBI in accordance
with the appropriate standard operating procedures
(SOPs) valid in the IMBI. A safety analysis will be based
on the set of all patients for which one of the interventions
was applied. Serious adverse events will be tabulated, ab-
solute and relative frequency, severity and the relationship
to the intervention will be given and compared between
the intervention groups.Discussion
DGE is a common complication after PD reported in nu-
merous studies, initially under the use of various defini-
tions [5,6]. Consequently, highly differing rates of DGE
were reported, which led to the introduction of the stan-
dardized definition of the ISGPS in 2007 [7]. The proposed
definition has been evaluated clinically in large patient
groups after ppPD and surprisingly shown an actual overall
DGE incidence of up to 45% [8].
DGE represents a therapeutically difficult complication
that prolongs patients’ hospital stay and postpones or
even inhibits the start of adjuvant chemotherapy in
tumor patients. Therefore, the need to reduce the fre-
quency of DGE is obvious. In two retrospective studies a
20% reduction of DGE after prPD was shown [9,10]. A
current randomized trial [11] confirmed a reduction of
DGE although the 13.7% difference between prPD and
ppPD in this study was less pronounced. As the number
of patients in these available studies is limited and the
study designs are heterogenous, evidence is still weak
and further studies are necessary to evaluate the actual
impact of prPD on DGE.
It remains unclear if pylorus resection influences the
severity of DGE in terms of the ISGPS grading A-C. Fur-
thermore, no standardized therapy of DGE is defined
yet, which impairs the significance of the respective
results. Reconstruction technique with stenting of the
pancreatic duct in the RCT [11] cannot be considered as
the standard reconstruction. As the overall fistula rate
was rather high in this study, this could have a substan-
tial influence on DGE. Postoperative nasogastric tube
management is not standardized. From our experience,
tube removal can be routinely done at the end of the
general anesthesia and may also influence stomach mo-
tility in the further course.
DGE is regarded as a functional impairment of gastric
motility and normal pyloric function, which has been
supported by the observation that antecolic reconstruction
of the duodeno-jejunal passage significantly lowered its
incidence, probably due to the advantage of less chemical
irritation by potential subclinical leakage of the pancreatic
anastomosis within the first postoperative days. An add-
itional anatomical modification by removing the pylorus
could significantly enhance this effect. Of course, resection
of the pylorus implies the risk of reflux symptoms in the
long-term follow-up. Yet, this has not been proven and
any long-term problems, for example gastric stump can-
cer after 10 to 15 years can be disregarded in pancreatic
cancer patients. In patients undergoing PD for benign
pathologies, however, these problems have to be taken
into account and should be evaluated in long-term stud-
ies. A differential surgical approach for malignant and
benign indications may be considered in case of clinic-
ally observed reflux-associated symptoms. Regarding
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studies on prPD show comparable results underlining
the feasibility of pylorus resection [9-11].
In conclusion, there is increasing evidence that prPD
may be associated with a decreased rate of DGE. The
present study as a large randomized trial based on the
currently available literature is planned to confirm these
findings, which may alter surgical procedures in PD.
Trial status
Recruiting
Enrolment of the first patient was performed in January
2013.
Appendix
Description of surgical and medical treatment
After confirmed respectability of the pancreatic process,
patients are randomized either to the pylorus-preserving
group or the pylorus-resecting group. When the pylorus
is preserved, the transsection toward the specimen is
carried out 1 cm distal to the pylorus by dividing the
duodenum with a linear stapling and cutting device
(GIA 75 mm, blue cartridge). In the pylorus resection
group, this transsection is performed 1 cm proximal to
the pylorus. Consequently, the stomach is divided by a
linear stapling and cutting device (GIA 75 mm, green
cartridge). The pylorus remains attached to the resection
specimen. The further surgical procedure of resection
and lymphadenectomy is carried out similarly in both
groups as usual and according to local standards regard-
ing the indication for the intervention.
After completion of the pancreatic and the bile duct
anastomosis, the gastro-enteric passage is restored by ei-
ther an end-to-side duodeno-jejunostomy in a two-layer
fashion, using running sutures PDS 4-0 or by an end-to
-side gastro-jejunostomy for which the same technique
is used (two-layer, running sutures PDS 4-0). The anas-
tomosis is located approximately 50 cm distal of the bile
duct anastomosis in an antecolic position in both
groups. A gastric tube is placed in the stomach without
passing the anastomosis. This tube is removed after re-
spiratory spontanization of the patient and removal of
the endotracheal tube after the operation.
The expertise of the surgeon (board certified versus no
certificate) who is performing the duodenal or gastric
anastomosis has to be documented.
Duration of surgery (time from skin cut until closure
(minutes)) and estimated blood loss (ml) will be
documented.
Permitted and not permitted medication(s)/
treatment(s)
Standard medical treatment includes prokinetic medica-
tion with metoclopramide 3 × 10 mg/day either i.v. ororally and proton pump inhibition with pantoprazole
1 × 40 mg i.v. or per os. Antibiotic treatment includes
the perioperative prophylaxis with mezlocillin and
metronidazole or ciprofloxacin and metronidazole in
case of an intolerance of penicillin-derived drugs. Add-
itional postoperative care is performed according to the
principles and standard of the department (pain treat-
ment, fluid resuscitation).
Nasogastric tubes are removed immediately after the op-
eration. Reinsertion is documented in the CRF with time
of reinsertion and duration of the treatment.
Octreotide analogs can be used in cases with ‘high-risk’
pancreatic anastomoses according to the department
guidelines. Antibiotics can be administered if necessary.
Erythromycin must not be used as an antibiotic agent. It
is administered in case of delayed gastric emptying as a
prokinetic drug for a three day period. Dosage, time of
application and duration of the treatment must be
recorded in the CRF.
Total parenteral nutrition is allowed in case of delayed
gastric emptying. Dosage, time of application and dur-
ation of the treatment must be recorded in the CRF.
The occurrence of a lymphatic fistula that requires nihil
per os treatment and total parenteral nutrition is a cri-
terion that excludes the patient from the study as this
interferes with the study endpoints.
Patients should receive the medical treatment according
to the clinical situation. Any protocol violation has to be
reported with a clear description in the CRF.
Endoscopic examination of the duodeno-jejunostomy or
gastro-jejunostomy, respectively will be performed in
case of DGE after three days of conservative treatment
without success. Dilation of the anastomosis can be per-
formed in case of suspected stenosis.
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